PMID- 35024639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 2666-3643 (Electronic)
IS  - 2666-3643 (Linking)
VI  - 3
IP  - 1
DP  - 2022 Jan
TI  - Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A 
      Multicenter Collaboration in Asia (ATORG-005).
PG  - 100261
LID - 10.1016/j.jtocrr.2021.100261 [doi]
LID - 100261
AB  - INTRODUCTION: Whereas interpatient heterogeneity in clinical characteristics and 
      treatment outcomes of NSCLC harboring a KRAS mutation is recognized, the 
      characterization of these patients in Asia has been limited. METHODS: A 
      multicenter, retrospective cohort study was conducted in eight academic centers 
      across Asia. Patients diagnosed with advanced NSCLC harboring a KRAS mutation and 
      who had received at least one line of anticancer therapy between January 2014 and 
      December 2018 were included. Modified time to next treatment (TTNT) was adopted 
      as a proxy for progression-free survival. RESULTS: A total of 216 patients were 
      analyzed. The median age at diagnosis of advanced NSCLC was 63.3 years, 70.8% 
      were men and 89.8% had adenocarcinoma. KRAS G12D was the most common subtype 
      (25.5%), followed by G12C (24.5%), and G12V (19.4%) The proportion of current or 
      former smokers was 65.7% in the overall population, with 86.8% in G12C and 58.9% 
      in non-G12C subgroups. For all treatments combined for the total population, the 
      first-line duration of therapy, modified TTNT, and TTNT were 4.5 (95% confidence 
      interval: 3.4-5.9), 6.2 (4.9-8.8), and 9.5 (7.1-11.4) months, respectively. The 
      median overall survival for the total population was 10.3 (6.9-12.4) months and 
      was prolonged in patients ever treated with immunotherapy (14.6 [8.6-19.1] versus 
      7.0 [5.9-10.6] mo, hazard ratio = 0.54, p < 0.001), with left truncation to 
      account for the time of KRAS testing. CONCLUSIONS: Whereas treatment outcomes 
      with conventional anticancer therapy are reasonable and immunotherapy looks 
      promising, the unmet need remains high for patients with KRAS-mutated NSCLC in 
      Asia, underscoring the need for novel therapeutic approaches.
CI  - (c) 2021 by the International Association for the Study of Lung Cancer.
FAU - Lee, Jiyun
AU  - Lee J
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Tan, Aaron C
AU  - Tan AC
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 
      Singapore.
FAU - Zhou, Siqin
AU  - Zhou S
AD  - Biostatistics and Epidemiology Unit, Clinical Trials and Epidemiological 
      Sciences, National Cancer Centre Singapore, Singapore.
FAU - Yoon, Shinkyo
AU  - Yoon S
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Liu, Siyang
AU  - Liu S
AD  - Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of 
      Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, School of Medicine, South China University 
      of Technology, Guangzhou, People's Republic of China.
FAU - Masuda, Ken
AU  - Masuda K
AD  - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Hayashi, Hidetoshi
AU  - Hayashi H
AD  - Department of Medical Oncology, Kindai University Faculty of Medicine, 
      Osaka-Sayama, Japan.
FAU - Batra, Ullas
AU  - Batra U
AD  - Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research 
      Centre, New Delhi, India.
FAU - Kim, Dong-Wan
AU  - Kim DW
AD  - Department of Internal Medicine, Clinical Trials Center, Seoul National 
      University Hospital, Cancer Research Institute, Seoul National University College 
      of Medicine, Seoul, Korea.
FAU - Goto, Yasushi
AU  - Goto Y
AD  - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Tan, Sze Huey
AU  - Tan SH
AD  - Biostatistics and Epidemiology Unit, Clinical Trials and Epidemiological 
      Sciences, National Cancer Centre Singapore, Singapore.
AD  - Biostatistics and Quantitative Epidemiology, Singapore Health Services, 
      Singapore, Singapore.
AD  - Oncology ACP, Duke-NUS Graduate Medical School, Singapore, Singapore.
FAU - Wu, Yi-Long
AU  - Wu YL
AD  - Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of 
      Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, School of Medicine, South China University 
      of Technology, Guangzhou, People's Republic of China.
FAU - Lee, Dae Ho
AU  - Lee DH
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Tan, Daniel S W
AU  - Tan DSW
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 
      Singapore.
FAU - Ahn, Myung-Ju
AU  - Ahn MJ
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20211204
PL  - United States
TA  - JTO Clin Res Rep
JT  - JTO clinical and research reports
JID - 101769967
PMC - PMC8728099
OTO - NOTNLM
OT  - Asian
OT  - Immunotherapy
OT  - KRAS
OT  - Non-small cell lung cancer
OT  - Overall survival
OT  - Time to next treatment
EDAT- 2022/01/14 06:00
MHDA- 2022/01/14 06:01
PMCR- 2021/12/04
CRDT- 2022/01/13 12:36
PHST- 2021/06/15 00:00 [received]
PHST- 2021/11/15 00:00 [revised]
PHST- 2021/11/19 00:00 [accepted]
PHST- 2022/01/13 12:36 [entrez]
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/01/14 06:01 [medline]
PHST- 2021/12/04 00:00 [pmc-release]
AID - S2666-3643(21)00120-X [pii]
AID - 100261 [pii]
AID - 10.1016/j.jtocrr.2021.100261 [doi]
PST - epublish
SO  - JTO Clin Res Rep. 2021 Dec 4;3(1):100261. doi: 10.1016/j.jtocrr.2021.100261. 
      eCollection 2022 Jan.